Market Research Logo

Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

Summary


GBI Research, a leading business intelligence provider, has released its latest research report,""Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations"".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.

The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.

Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.

Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.

Scope

The report covers and includes -

  • An introduction to asthma, including discussion of disease epidemiology, etiology pathophysiology, symptoms, diagnosis, and treatment, with clinical data for drugs featured in the current treatment algorithm discussed in detail
  • In-depth analysis of the current marketed products landscape, including product profiles of the main drugs used and heat maps that compare their safety and efficacy parameters
  • Comprehensive analysis of the asthma pipeline by phase of development, molecule type, and molecular target and novelty, and comparative analysis of the most promising late-stage pipeline drugs, as well as heat maps and a competitor matrix that compares safety and efficacy parameters
  • Additional in-depth analysis of the asthma clinical trials landscape, including trends in size, duration and failure rate
  • Forecast projections for the asthma market to 2020, including analysis of the global market and each of the eight major markets and incorporating projected, low, and high-variance scenarios based on treatment usage patterns and annual cost of therapy in each of the major markets
  • Discussion of the strategic consolidations landscape, including trends in co-development and licensing deals relevant to asthma drug products
Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches by allowing them to -
  • Gain a comprehensive understanding of asthma, including diagnosis, disease severity, and treatment algorithms
  • Understand the current asthma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved
  • Identify trends, developments, and prominent molecule types and molecular targets within the asthma pipeline
  • Gain an appreciation of the clinical and commercial aspects of the most promising late-stage pipeline molecules and their potential competitive impact on the future market
  • Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration and failure rate, phase of development, molecule type, and molecular target
  • Observe projections for treatment usage patterns, annual therapy costs, and market growth in the eight major markets and understand reasons for variance in projected patterns of growth


US Asthma Treatment Market Value to Hit $14 Billion by 2020, says GBI Research

The US treatment market for asthma will rise in value from $11.7 billion in 2013 to an estimated $14 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 2.6%, says business intelligence provider GBI Research.

The company’s latest report* states that the US is the single biggest asthma treatment market globally, reflecting the country’s large population size, high disease prevalence and the inflated cost of therapeutics in comparison with other major markets.

However, according to Fiona Chisholm, Associate Analyst for GBI Research, the asthma therapeutics market will be strongly characterized by generic erosion that will impact several of the leading brands over the forecast period, including Singulair (montelukast sodium), Advair (fluticasone propionate/salmeterol xinafoate), and Symbicort (budesonide/formoterol fumarate).

Chisholm explains: “Singulair’s patent expired in 2012, with the US Food and Drug Administration subsequently granting approval to several manufacturers, including Teva, Sandoz and Mylan, to market generic versions of the drug. As a consequence, sales revenue for Singulair has declined substantially in recent years.

“Advair and Symbicort have also recently lost patent protection in the US. However, substantial generic erosion has not occurred, due to regulatory hurdles and the difficulties inherent in trying to produce a bioequivalent Inhaled Corticosteroid/Long-Acting Beta Agonist (ICS/LABA) combination drug and inhaler device.”

While patent expirations are set to limit market growth to 2020, the impact of this will be offset by the uptake of recently approved and promising pipeline drugs.

Chisholm continues: “Arnuity, the follow-on product to the current ICS market leader Flovent, was approved in the US in August 2014, while Relvar, the follow-on product to the current ICS/LABA market leader Advair, is at the pre-registration phase. GBI Research believes both drugs will help to maintain sales revenue for their respective classes.

“Furthermore, the potential approval of several premium-priced, novel IL-targeting monoclonal antibodies, although limited by their target populations, will also contribute to growth.”

The analyst adds that the development of these IL-targeting therapies, as well as other novel drugs, also gives rise to potential phenotype-targeted treatment, which could be particularly useful for patients with severe asthma.

“If approved, these drugs will represent a significant step forward in asthma therapeutics, helping to achieve personalized treatment tailored to each individual patient,” Chisholm concludes.

*Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

This report provides analysis of the current marketed and pipeline products landscape for asthma treatment, including annualized market data from 2013 and forecast to 2020 across eight major markets, namely the US, France, Spain, Germany, Italy, UK, Japan and Canada.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Disease Introduction
    • Epidemiology
    • Etiology
    • Pathophysiology
    • Symptoms
    • Diagnosis
    • Assessment of Disease Severity
      • Table Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-4 Years of Age
      • Table Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-11 Years of Age
      • Table Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths ¡Ý 12 Years of Age and Adults
    • Treatment
    • Treatment Algorithm
      • Table Management of Chronic Asthma
      • Table Management of Acute Asthma
    • Treatment Segments
      • Table Asthma Clinical Trial Endpoints
      • ICS Monotherapy for the Maintenance Treatment of Asthma
      • Singulair (montelukast sodium) as First-Line Maintenance Therapy
      • ICS/LABA Combination Therapy
      • Add-on Therapies
  • Marketed Products
    • Overview
    • ICS for the Maintenance Treatment of Asthma
      • Arnuity (fluticasone furoate) - GSK
    • ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma
      • Advair (fluticasone propionate and salmeterol xinafoate) - GSK
      • Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-Promotion with Astellas Pharma
      • Dulera (mometasone furoate and formoterol fumarate) - Merck
      • Relvar/Breo (vilanterol trifenatate and fluticasone furoate) - GlaxoSmithKline/Theravance
    • Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma
      • Xolair (omalizumab) - Novartis and Genentech
      • Singulair (montelukast) - Merck
      • Spiriva (tiotropium bromide) - Boehringer Ingelheim
    • Heat Maps for Marketed Products
      • Table Figure 1: Asthma Therapeutics Market, Global, Heat Map for Marketed Products, 2015
      • Table Figure 2: Asthma Therapeutics Market, Global, Heat Map for Marketed Products (continued), 2015
  • Asthma Pipeline
    • Overview
    • Pipeline Analysis by Stage of Development, Molecule Type and Program Type
      • Table Figure 3: Asthma Therapeutics Market, Global, Pipeline, 2015
    • Pipeline Analysis by Molecular Target
      • Table Figure 4: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, 2015
      • Table Figure 5: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of Immune/Inflammatory System Targets and Cytokine/Cytokine Receptor Targets, 2015
      • Table Figure 6: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of Enzyme and Kinase Molecular Targets, 2015
      • Table Figure 7: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of Adrenergic and Cholinergic Receptors, 2015
    • Asthma Clinical Trial Landscape
      • Clinical Trial Failure Rates
        • Table Figure 8: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate, 2006-2014
        • Table Figure 9: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2014
        • Table Figure 10: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2014
      • Clinical Trial Duration
        • Table Figure 11: Asthma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type, (months), 2006-2014
        • Table Figure 12: Asthma Therapeutics Market, Global, Phase I Clinical Trial Duration by Molecular Target (months), 2006-2014
        • Table Figure 13: Asthma Therapeutics Market, Global, Phase II Clinical Trial Duration by Molecular Target (months), 2006-2014
        • Table Figure 14: Asthma Therapeutics Market, Global, Phase III Clinical Trial Duration by Molecular Target (months), 2006-2014
      • Clinical Trial Size
        • Table Figure 15: Asthma Therapeutics Market, Global, Clinical Trial Recruitment Size by Stage of Development and Molecule Type for Individual Asthma Products (participants), 2006-2014
        • Table Figure 16: Asthma Therapeutics Market, Global, Clinical Trial Recruitment Size by Stage of Development and Molecule Type for Individual Asthma Clinical Trials (participants), 2006-2014
        • Table Figure 17: Asthma Therapeutics Market, Global, Phase I Clinical Trial Recruitment Size by Molecular Target (participants), 2006-2014
        • Table Figure 18: Asthma Therapeutics Market, Global, Phase II Clinical Trial Recruitment Size by Molecular Target (participants), 2006-2014
        • Table Figure 19: Asthma Therapeutics Market, Global, Phase III Clinical Trial Recruitment Size by Molecular Target (participants), 2006-2014
      • Comparative Clinical Trial Metrics Analysis
        • Table Figure 20: Asthma Therapeutics Market, Global, Failure Rate (%), Average Clinical Trial Duration (months) and Average Recruitment Size for Asthma by Molecule Type, 2006-2014
        • Table Figure 21: Asthma Therapeutics Market, Global Failure Rate (%), Average Clinical Trial Duration (months) and Average Trial Recruitment Size (participants) for Asthma by Molecular Target, 2006-2014
    • Promising Pipeline Molecules
      • Mepolizumab - GSK
        • Table Figure 22: Asthma Therapeutics Market, Global, Mepolizumab Forecast ($bn), 2015-2020
      • Reslizumab - Teva Pharmaceutical
        • Table Figure 23: Asthma Therapeutics Market, Global, Reslizumab Forecast ($bn), 2016-2020
      • Lebrikizumab - Roche/Genentech
        • Table Figure 24: Asthma Therapeutics Market, Global, Lebrikizumab Forecast ($m), 2018-2020
      • Dupilumab - Regeneron Pharmaceuticals in Collaboration with Sanofi
        • Table Figure 25: Asthma Therapeutics Market, Global, Dupilumab Forecast ($m), 2018-2020
      • Masitinib - AB Science
        • Table Figure 26: Asthma Therapeutics Market, Global, Masitinib Forecast ($m), 2017-2020
    • Heat Map and Competitor Matrix for Pipeline Products
      • Table Figure 27: Asthma Therapeutics Market, Global, Heat Map for Pipeline Products, 2015
      • Table Figure 28: Asthma Therapeutics Market, Global, Competitor Matrix for Marketed and Pipeline Products, 2015
  • Market Forecast to 2020
    • Geographical Markets
    • Global Market
      • Table Figure 29: Asthma Therapeutics Market, Global, Treatment Patterns, 2013-2020
      • Table Figure 30: Asthma Therapeutics Market, Global, Market Size ($bn), 2013-2020
    • North America
      • Treatment Usage Patterns
        • Table Figure 31: Asthma Therapeutics Market, North America, Treatment Patterns, 2013-2020
      • Annual Cost of Therapy
        • Table Figure 32: Asthma Therapeutics Market, North America, Annual Cost of Therapy ($), 2013-2020
      • Market Size
        • Table Figure 33: Asthma Therapeutics Market, North America, Market Size, 2013-2020
    • Top Five Countries of Europe
      • Treatment Usage Patterns
        • Table Figure 34: Asthma Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2013-2020
      • Annual Cost of Therapy
        • Table Figure 35: Asthma Therapeutics Market, Top Five EU Countries, Annual Cost of Therapy ($), 2013-2020
      • Market Size
        • Table Figure 36: Asthma Therapeutics Market, Top Five EU Countries, Market Size, 2013-2020
    • Japan
      • Treatment Usage Patterns
        • Table Figure 37: Asthma Therapeutics Market, Japan, Treatment Patterns, 2013-2020
      • Annual Cost of Therapy
        • Table Figure 38: Asthma Therapeutics Market, Japan, Annual Cost of Therapy ($), 2013-2020
      • Market Size
        • Table Figure 39: Asthma Therapeutics Market, Japan, Market Size ($bn), 2013-2020
    • Drivers and Barriers for the Asthma Market
      • Drivers
      • Barriers
  • Strategic Consolidations
    • Co-development Deals
      • Table Figure 40: Asthma Therapeutics Market, Global, Co-Development Deals by Region, 2006-2014
      • Table Figure 41: Asthma Therapeutics Market, Global, Co-Development Deals by Value ($m), 2006-2014
      • Table Figure 42: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-Development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2014
      • Table Figure 43: Asthma Therapeutics Market, Global, Co-Development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2014
      • Table Figure 44: Asthma Therapeutics Market, Global, Co-Development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2014
      • Table Figure 45: Asthma Therapeutics Market, Global, Co-Development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2014
      • Sepracor Enters into Co-Development Agreement with Nycomed for Ciclesonide
      • NeoStem Enters into Agreement with University of California to Develop Human Regulatory T Cells
      • Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies
    • Licensing Deals
      • Table Figure 46: Asthma Therapeutics Market, Global, Licensing Deals by Region, 2006-2014
      • Table Figure 47: Asthma Therapeutics Market, Global, Licensing Deals by Value ($m), 2006-2014
      • Table Figure 48: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2014
      • Table Figure 49: Asthma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2014
      • Table Figure 50: Asthma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2014
      • Table Figure 51: Asthma Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2014
      • Amgen Enters into Licensing Agreement with Kyowa Hakko Kirin - Terminated
      • Mundipharma Enters into Licensing Agreement with SkyePharma
      • MAP Pharmaceuticals Enters into Licensing Agreement with AstraZeneca - Terminated
      • Orexo Enters into Licensing Agreement with Janssen Pharmaceuticals - Terminated
      • Aslan Pharma Enters into Licensing Agreement with CSL for CSL-334
  • Appendix
    • All Pipeline Drugs by Phase of Development
      • Discovery
        • Table Asthma Therapeutics, Global, All Pipeline Products, Discovery Phase, 2015
      • Preclinical
        • Table Asthma Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2015
      • Phase I
        • Table Asthma Therapeutics, Global, All Pipeline Products, Phase I, 2015
      • Phase II
        • Table Asthma Therapeutics, Global, All Pipeline Products, Phase II, 2015
      • Phase III
        • Table Asthma Therapeutics, Global, All Pipeline Products, Phase III, 2015
      • Pre-registration
        • Table Asthma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2015
    • Market Forecasts to 2020
      • Global
        • Table Asthma Therapeutics Market, Global, Market Forecast, 2013-2020
      • US
        • Table Asthma Therapeutics Market, US, Market Forecast, 2013-2020
      • Canada
        • Table Asthma Therapeutics Market, Canada, Market Forecast, 2013-2020
      • UK
        • Table Asthma Therapeutics Market, UK, Market Forecast, 2013-2020
      • France
        • Table Asthma Therapeutics Market, France, Market Forecast, 2013-2020
      • Germany
        • Table Asthma Therapeutics Market, Germany, Market Forecast, 2013-2020
      • Italy
        • Table Asthma Therapeutics Market, Italy, Market Forecast, 2013-2020
      • Spain
        • Table Asthma Therapeutics Market, Spain, Market Forecast, 2013-2020
      • Japan
        • Table Asthma Therapeutics Market, Japan, Market Forecast, 2013-2020
    • References
    • Abbreviations
    • Research Methodology
      • Secondary Research
      • Marketed Product Profiles
      • Late-Stage Pipeline Candidates
      • Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
      • Product Competitiveness Framework
      • Pipeline Analysis
      • Forecasting Model
      • Deals Data Analysis
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report